Skip to main content

Clinical Trial Results


Dr. Dominick Angiolillo Presents: From Dual Antiplatelet Treatment Regimens With Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition With Low-Dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease: The SWAP-AC Study

Loader Loading…
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab


Disclosures: TBD